Cybin Inc. (NASDAQ:HELP - Get Free Report)'s share price fell 7.7% during trading on Tuesday. The company traded as low as $7.31 and last traded at $7.0820. Approximately 489,730 shares changed hands during trading, a decline of 63% from the average session volume of 1,330,713 shares. The stock had previously closed at $7.67.
Analyst Ratings Changes
Several equities analysts have weighed in on HELP shares. TD Cowen increased their target price on Cybin from $8.00 to $62.00 and gave the company a "buy" rating in a research note on Thursday, August 20th. Wells Fargo & Company boosted their target price on Cybin from $16.00 to $22.00 and gave the stock an "overweight" rating in a research report on Thursday, October 22nd. Barclays began coverage on Cybin in a research note on Friday, September 18th. They issued an "overweight" rating and a $35.00 price target for the company. Finally, Wall Street Zen downgraded shares of Cybin from a "sell" rating to a "strong sell" rating in a research report on Saturday, November 7th. Six analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $47.33.
Check Out Our Latest Report on HELP
Cybin Trading Down 3.9%
The firm's fifty day moving average price is $11.15 and its 200-day moving average price is $7.81. The company has a market cap of $588.28 million, a price-to-earnings ratio of -2.46 and a beta of 0.64.
Cybin (NASDAQ:HELP - Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.74). As a group, research analysts anticipate that Cybin Inc. will post -2.95 EPS for the current year.
Insiders Place Their Bets
In other Cybin news, CFO Greg Cavers purchased 3,000 shares of the company's stock in a transaction dated Tuesday, September 29th. The shares were bought at an average price of $12.91 per share, with a total value of $38,730.00. Following the completion of the transaction, the chief financial officer directly owned 3,000 shares in the company, valued at $38,730. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric H. L. So purchased 100,000 shares of the company's stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average cost of $12.39 per share, for a total transaction of $1,239,000.00. Following the transaction, the insider owned 4,465,014 shares of the company's stock, valued at $55,321,523.46. This trade represents a 2.29% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 688,000 shares of company stock valued at $8,422,830 over the last ninety days. 15.00% of the stock is owned by insiders.
Institutional Trading of Cybin
Several hedge funds have recently bought and sold shares of HELP. Goldman Sachs Group Inc. acquired a new position in shares of Cybin in the third quarter valued at approximately $568,000. Great Point Partners LLC acquired a new stake in shares of Cybin during the third quarter worth $3,944,000. Integral Health Asset Management LLC bought a new stake in Cybin in the 3rd quarter valued at $6,145,000. Blue Owl Capital Holdings LP lifted its position in Cybin by 381.2% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 288,282 shares of the company's stock valued at $3,543,000 after acquiring an additional 228,371 shares in the last quarter. Finally, State Street Corp bought a new stake in Cybin in the 3rd quarter valued at $363,000. 17.94% of the stock is currently owned by institutional investors and hedge funds.
Cybin Company Profile
(
Get Free Report)
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company's pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.